+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia



The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia



Value in Health Regional Issues 20: 60-65



To evaluate the public health benefits and economic value of live-attenuated yellow fever (YF) 17D vaccine in Colombia. A decision tree model was used to assess the theoretical impact of routine YF vaccination of 1-year-olds (no "catch-up") during the interepidemic period from 1980 to 2002, avoiding capturing the impact of YF vaccine introduction in 2003. The vaccine was assumed to be 99% effective, to provide lifetime protection, and to cover 85% of the target population. Costs per disability-adjusted life-year (DALY) averted were computed from payer and societal perspectives. Univariate sensitivity analyses were performed. During the interepidemic period, routine YF vaccination would have averted 2223 nonfatal cases of YF and 65 deaths, leading to an overall reduction of 1365 DALYs. The net cost of this vaccination would have been $25 964 813 (payer's perspective) and $16 535 465 (societal perspective). Cost per DALY averted was $19 022 and $12 114 from payer and societal perspectives, respectively (all costs in 2015 US dollars). Vaccination was considered cost-effective from both perspectives (ie, between 1- and 3-fold the gross domestic product per capita, $7158) and remains so if price per dose was $2.75 or less and $4.66 from payer and societal perspectives, respectively. Underreporting had the largest impact on the results. Routine toddler YF vaccination in Colombia would have been considered cost-effective in the prevaccination era. This study provides insights on the value of vaccination in an upper middle-income country.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066681369

Download citation: RISBibTeXText

PMID: 30974312

DOI: 10.1016/j.vhri.2019.01.004


Related references

Public Health and Economic Benefits of Quadrivalent Influenza Vaccine in Colombia. Value in Health 18(7): A590, 2015

Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study. Journal of Infectious Diseases 214(6): 854-861, 2016

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Human Vaccines and Immunotherapeutics 8(3): 312-322, 2012

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. Bmc Public Health 14(): 813-813, 2015

The efficacy of vaccination in the prevention of yellow fever in Colombia. Amer Jour Hyg 39(1): 58-66, 1944

A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. Plos one 11(3): E0149871, 2016

Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Review of Vaccines 11(4): 427-448, 2012

Application of PHEL (Public Health Epidemiological Logic) in devising a vaccination policy: a broad public health criteria-for routine Immunization. Human Vaccines 7(5): 576-578, 2011

Rural and Jungle Yellow Fever-A new Publie Health Problem in Colombia. Rural and Jungle Yellow Fever-A new Publie Health Problem in Colombia, Bogota., 4to, 42, 1935

Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. American Journal of Tropical Medicine and Hygiene 12: 230-235, 1963

Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 22(9-10): 1073-1078, 2004

Immunological studies with Group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Amer Jour Trop Med And Hyg 12(2): 230-235, 1962

Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination. American Journal of Tropical Medicine and Hygiene 87(6): 1112-1115, 2012

Intervene before leaving: clustered lot quality assurance sampling to monitor vaccination coverage at health district level before the end of a yellow fever and measles vaccination campaign in Sierra Leone in 2009. Bmc Public Health 12: 415, 2012

Routine vaccination in children from the public health standpoint. Archivos de Pediatria del Uruguay 33: 712-723, 1962